Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?
M Ghielmetti, HD Schaufelberger, G Mieli-Vergani… - Journal of …, 2021 - Elsevier
Autoimmune phenomena and clinically apparent autoimmune diseases, including
autoimmune hepatitis, are increasingly been reported not only after natural infection with the …
autoimmune hepatitis, are increasingly been reported not only after natural infection with the …
Molecular and cellular aspects of protein misfolding and disease
E Herczenik, MFBG Gebbink - The FASEB Journal, 2008 - Wiley Online Library
Proteins are essential elements for life. They are building blocks of all organisms and the
operators of cellular functions. Humans produce a repertoire of at least 30,000 different …
operators of cellular functions. Humans produce a repertoire of at least 30,000 different …
Drug-induced liver injury associated with statins
MW Russo, M Scobey… - Seminars in Liver …, 2009 - thieme-connect.com
The “statins,” or hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors, are a
generally safe class of drugs that are widely used throughout the world and are rarely …
generally safe class of drugs that are widely used throughout the world and are rarely …
[HTML][HTML] Statins attenuate outgrowth of breast cancer metastases
Background Metastasis in breast cancer foreshadows mortality, as clinically evident disease
is aggressive and generally chemoresistant. Disseminated breast cancer cells often enter a …
is aggressive and generally chemoresistant. Disseminated breast cancer cells often enter a …
[HTML][HTML] Statin-induced liver injury patterns: a clinical review
LD Averbukh, A Turshudzhyan, DC Wu… - Journal of Clinical and …, 2022 - ncbi.nlm.nih.gov
Since their introduction in 1987, hydroxymethyl glutaryl coenzyme A reductase (HMG-CoA)
inhibitors, more commonly known as statins, have become some of the most widely …
inhibitors, more commonly known as statins, have become some of the most widely …
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia
MS Kostapanos, HJ Milionis, MS Elisaf - American journal of …, 2010 - Springer
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
[HTML][HTML] Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
T Yuan, R Wu, W Wang, Y Liu, W Kong… - Frontiers in …, 2023 - frontiersin.org
Introduction: Colorectal cancer is one of the most prevalent life-threatening malignant tumors
with high incidence and mortality. However, the efficacy of current therapeutic regimens is …
with high incidence and mortality. However, the efficacy of current therapeutic regimens is …
Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, anti-hyperlipidemic and anti-oxidant activity
Rosuvastatin is a hypolipidemic drug of limited oral bioavailability. The aim was to develop
rosuvastatin flexible chitosomes and loading into a pullulan-based tablet to improve the …
rosuvastatin flexible chitosomes and loading into a pullulan-based tablet to improve the …
[PDF][PDF] Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management
J Ehtisham, M Altieri, E Salamé, E Saloux… - Liver …, 2010 - Wiley Online Library
The prevalence of coronary artery disease in end‐stage liver disease is only now being
recognized. Liver transplant patients are a high risk subgroup for coronary artery disease …
recognized. Liver transplant patients are a high risk subgroup for coronary artery disease …
他汀类药物的临床应用及不良反应研究进展
张冰, 王莉莉 - 国际药学研究杂志, 2013 - cqvip.com
他汀类药物是一线降脂药物, 也是心血管疾病的预防药物, 临床应用和研究范围正不断扩大.
他汀类药物临床应用研究主要关注心血管疾病一级预防, 充血性心力衰竭的治疗 …
他汀类药物临床应用研究主要关注心血管疾病一级预防, 充血性心力衰竭的治疗 …